European Medical Solutions (ALEMS) Fair Value & Analysis
Healthcare · BE · Market cap €22.0M
Fair value as of: Jun 24, 2026
Analysis
European Medical Solutions (ALEMS) currently trades at €4.92, while our model-based Fair Value estimate is €8.55 — implying the stock looks roughly 73.8% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
European Medical Solutions engages in the design, development, and manufacturing of medical imaging systems for digital radiology and bone densitometry in Belgium and internationally. It offers R/F solutions, including PLATINUM NEO, a solution that revolutionizes the R/F workflow through an interface and AI-powered image processing; OPTIMA, a performance remote-controlled table designed to provide, imaging solution for radiography and fluoroscopy examinations; bone densitometry and body composition analysis equipment; chest and bone rooms, such as floor and ceiling tube stands; ambulatory radiography equipment; retrofit kits; C-ARM mobile operating room solutions; and mammography solutions. The company was formerly known as DMS Imaging SA and changed its name to European Medical Solutions in June 2024. DMS Imaging SA was founded in 1979 and is headquartered in Ixelles, Belgium. European Medical Solutions operates as a subsidiary of Diagnostic Medical Systems S.A.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is European Medical Solutions (ALEMS) undervalued?
What is the fair value of ALEMS?
What is the quality score of ALEMS?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.